These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 26458194)
1. Targeting Central Nervous System B Cells in Progression of Multiple Sclerosis: Is Intrathecal Anti-CD20 a Therapeutic Option? Fereidan-Esfahani M; Brück W; Weber MS JAMA Neurol; 2015 Dec; 72(12):1407-8. PubMed ID: 26458194 [No Abstract] [Full Text] [Related]
2. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. Studer V; Rossi S; Motta C; Buttari F; Centonze D J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066 [TBL] [Abstract][Full Text] [Related]
3. CD21 positive B cell: a novel target for treatment of multiple sclerosis. Farjam M; Ebrahimpour A; Fakhraei B Med Hypotheses; 2013 May; 80(5):556-7. PubMed ID: 23384704 [TBL] [Abstract][Full Text] [Related]
4. The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies. Li R; Bar-Or A Cold Spring Harb Perspect Med; 2019 Apr; 9(4):. PubMed ID: 29661809 [TBL] [Abstract][Full Text] [Related]
5. Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. Zanotti C; Chiarini M; Serana F; Sottini A; Garrafa E; Torri F; Caimi L; Rasia S; Capra R; Imberti L Clin Immunol; 2012 Oct; 145(1):19-26. PubMed ID: 22892399 [TBL] [Abstract][Full Text] [Related]
6. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Vugmeyster Y; Howell K; Bakshl A; Flores C; Canova-Davis E Cytometry A; 2003 Apr; 52(2):101-9. PubMed ID: 12655653 [TBL] [Abstract][Full Text] [Related]
10. B cells: no longer the nondominant arm of multiple sclerosis. Klawiter EC; Cross AH Curr Neurol Neurosci Rep; 2007 May; 7(3):231-8. PubMed ID: 17488589 [TBL] [Abstract][Full Text] [Related]
11. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Vugmeyster Y; Howell K; McKeever K; Combs D; Canova-Davis E Int Immunopharmacol; 2003 Oct; 3(10-11):1477-81. PubMed ID: 12946444 [TBL] [Abstract][Full Text] [Related]
12. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Kulik L; Chen K; Huber BT; Holers VM Mol Immunol; 2011 Mar; 48(6-7):883-94. PubMed ID: 21269698 [TBL] [Abstract][Full Text] [Related]
13. Use of interferon-beta in the treatment of multiple sclerosis. Derwenskus J; Lublin FD Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838 [No Abstract] [Full Text] [Related]
14. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis]. García-Merino JA; Sánchez AJ Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407 [TBL] [Abstract][Full Text] [Related]
15. Bedside to bench: betting on B cells in multiple sclerosis. Link H Nat Med; 2008 Jun; 14(6):615-6. PubMed ID: 18535578 [No Abstract] [Full Text] [Related]
16. The B lymphocyte as an immunotherapeutic target. Fearon DT QJM; 1995 Mar; 88(3):149-53. PubMed ID: 7539331 [No Abstract] [Full Text] [Related]
17. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much? Giacomini PS; Arnold DL; Bar-Or A; Antel JP Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295 [No Abstract] [Full Text] [Related]
18. Intrathecal immune reset in multiple sclerosis: exploring a new concept. Bonnan M Med Hypotheses; 2014 Mar; 82(3):300-9. PubMed ID: 24417802 [TBL] [Abstract][Full Text] [Related]
19. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519 [TBL] [Abstract][Full Text] [Related]
20. New concepts in the immunopathogenesis of multiple sclerosis. Hemmer B; Archelos JJ; Hartung HP Nat Rev Neurosci; 2002 Apr; 3(4):291-301. PubMed ID: 11967559 [No Abstract] [Full Text] [Related] [Next] [New Search]